Ac4ManNAz
Based on 17 publication(s) in Google Scholar
Ac4ManNAz can be taken up by cells and is an azide-containing metabolic glycoprotein labeling reagent that selectively modifies proteins. Commonly used for cell labeling, tracking and proteomic analysis. Ac4ManNAz contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Ac4ManNAz can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
For research use only. We do not sell to patients.
- Purity : 99.94%
- CAS No.: 1213701-11-1
- Formula: C16H22N4O10
- Molecular Weight:430.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Ac4ManNAz
More- Adv Mater. 2025 Sep;37(35):e2420113. [Abstract]
- Adv Mater. 2025 Jul 7:e2504733. [Abstract]
- J Extracell Vesicles. 2026 Apr;15(4):e70282. [Abstract]
- Adv Funct Mater. 2025 Nov 12.
- ACS Nano. 2025 May 27;19(20):18986-18995. [Abstract]
- Acta Pharm Sin B. 2025 Dec 23.
- Adv Sci (Weinh). 2026 May 6:e75519. [Abstract]
- Adv Sci (Weinh). 2025 Apr;12(13):e2416841. [Abstract]
- Acta Biomater. 2026 Jul:218:510-524. [Abstract]
- Acta Pharmacol Sin. 2025 Aug 8. [Abstract]
- Acta Biomater. 2025 Apr 10:S1742-7061(25)00265-X. [Abstract]
- Int J Nanomedicine. 2025 Nov 26:20:14185-14200. [Abstract]
- Anal Chem. 2026 Mar 24;98(11):8143-8154. [Abstract]
- Talanta. 2026 Jul 1:304:129561. [Abstract]
- Oncogenesis. 2025 Oct 1;14(1):29. [Abstract]
- Biophys J. 2026 Mar 13:S0006-3495(26)00198-0. [Abstract]
- bioRxiv. 2025 Aug 08.
-
Others
-
RT-PCR
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
RT-PCR
Biological Activity
Description
In Vitro
Ac4ManNAz (0-50 μM, 72 h) upregulates MAPK activity-related genes (TLR4, THBS1, FPR1) and downregulates cell cycle, proliferation and cell adhesion-related genes like CYBB, GABRA1, SLC6A2, AKAP7)[2].
Ac4ManNAz (0-50 μM, 30 h) inhibits voltage-gated potassium channel, inhibits the cell migration and invasion in A549, and impairs the mitochondrial functions[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549
-
Concentration:50 μM
-
Incubation Time:30 h
-
Result:Inhibited cell migration.
Chemical Information
-
CAS No. 1213701-11-1
-
Appearance Solid
-
Molecular Weight 430.37
-
Formula C16H22N4O10
-
Color White to off-white
-
SMILES
CC(O[C@@H]1[C@@H]([C@H](O[C@@H]([C@H]1OC(C)=O)COC(C)=O)OC(C)=O)NC(CN=[N+]=[N-])=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Adv Mater
Dendritic Cell-Based Biohybrid Immunomodulator Alleviates Intestinal Inflammatory Disease. [Abstract]2025 Sep;37(35):e2420113. PMID: 40545797 -
Adv Mater
A Dendritic Cell-Nanogel Conjugate for Tumor-Draining Lymph Node-Specific PD-L1 Blockade. [Abstract]2025 Jul 7:e2504733. PMID: 40619999
Ac4ManNAz purchased from MedChemExpress. Usage Cited in: Adv Mater. 2025 Jul 7:e2504733. [Abstract]
Scheme illustration of the preparation of tumor-lysate pulsed DC vaccines (DCVs). BMDCs were incubated with 50 μM Ac4ManNAz and tumor lysates for 48 h.
-
J Extracell Vesicles
PREDICTOR: A Non-Enzymatic Catalytic Cascade Tool for in Situ Visualization of Small Extracellular Vesicle Surface glycoRNAs. [Abstract]2026 Apr;15(4):e70282. PMID: 41979055 -
-
ACS Nano
Decoration of Biomimetic DNA Receptors on Macrophages for Precise and Logical Manipulation of Pathogen Predation. [Abstract]2025 May 27;19(20):18986-18995. PMID: 40358040 -
-
Adv Sci (Weinh)
Light-Switched Mesenchymal Stem Cells for In Situ Exosome Amplification in Craniofacial Bone Defect Reconstruction. [Abstract]2026 May 6:e75519. PMID: 42089450 -
Adv Sci (Weinh)
A Spatially Distributed Microneedle System for Bioorthogonal T Cell-Guided Cancer Therapy. [Abstract]2025 Apr;12(13):e2416841. PMID: 39921874 -
Acta Biomater
Strain-promoted click chemistry boosts microbubbles for targeted ultrasound imaging and cancer chemotherapy. [Abstract]2026 Jul:218:510-524. PMID: 42248283 -
Acta Pharmacol Sin
Dendritic cell-liposome conjugates reverse immunosuppressive tumor microenvironment for inhibiting colitis-associated colorectal cancer. [Abstract]2025 Aug 8. PMID: 40781495 -
Acta Biomater
Engineered bioorthogonal cell delivery system for in situ antimicrobial peptide recruitment during systemic bacterial infection. [Abstract]2025 Apr 10:S1742-7061(25)00265-X. PMID: 40220946 -
Int J Nanomedicine
Interleukin-2 Surface Displayed M1 Macrophage-Derived Extracellular Vesicles for Modulating the Tumor Microenvironment. [Abstract]2025 Nov 26:20:14185-14200. PMID: 41332502
Ac4ManNAz purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Nov 26:20:14185-14200. [Abstract]
Ac4ManNAz (50 μM; 72 h). qRT-PCR analysis comparing the relative expression level of IL-1β between M1 macrophages and Ac4ManNAz-treated M1 macrophages (Ac4/M1).
Ac4ManNAz purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Nov 26:20:14185-14200. [Abstract]
Ac4ManNAz (50 μM; 72 h). Fluorescence microscopy imaging of macrophages labeled with DBCO-Cy5 after Ac4ManNAz treatment. Hoechst staining shows nuclei (blue), while DBCO-Cy5 indicates successful surface labeling (red). The merged image highlights specific azide-dependent bioorthogonal chemistry, with scale bars representing 100 µm.
Ac4ManNAz purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Nov 26:20:14185-14200. [Abstract]
Ac4ManNAz (50 μM; 72 h). Morphological comparison of M0, M1, and Ac4ManNAz-treated M1 macrophages.
Ac4ManNAz purchased from MedChemExpress. Usage Cited in: Int J Nanomedicine. 2025 Nov 26:20:14185-14200. [Abstract]
Ac4ManNAz (50 μM; 72 h). qRT-PCR results showing that with Ac4ManNAz-treated M1EV (Ac4M1EV) significantly upregulated M1 macrophage markers IL-1β and CXCL10, while downregulating the M2 macrophage marker CD206 compared with M0 macrophages.
-
Anal Chem
2026 Mar 24;98(11):8143-8154. PMID: 41810699 -
Talanta
Dual-gold nanoprobe system enables highly sensitive SERS detection of glycosylated CEs1 in HepG-2 cell culture supernatant. [Abstract]2026 Jul 1:304:129561. PMID: 41722413 -
Oncogenesis
2025 Oct 1;14(1):29. PMID: 41028727 -
Biophys J
Inhibition of endocytosis by glycans arises from steric rather than electrostatic repulsion. [Abstract]2026 Mar 13:S0006-3495(26)00198-0. PMID: 41832605 -
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (232.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3236 mL | 11.6179 mL | 23.2358 mL | 58.0896 mL |
| 5 mM | 0.4647 mL | 2.3236 mL | 4.6472 mL | 11.6179 mL | |
| 10 mM | 0.2324 mL | 1.1618 mL | 2.3236 mL | 5.8090 mL | |
| 15 mM | 0.1549 mL | 0.7745 mL | 1.5491 mL | 3.8726 mL | |
| 20 mM | 0.1162 mL | 0.5809 mL | 1.1618 mL | 2.9045 mL | |
| 25 mM | 0.0929 mL | 0.4647 mL | 0.9294 mL | 2.3236 mL | |
| 30 mM | 0.0775 mL | 0.3873 mL | 0.7745 mL | 1.9363 mL | |
| 40 mM | 0.0581 mL | 0.2904 mL | 0.5809 mL | 1.4522 mL | |
| 50 mM | 0.0465 mL | 0.2324 mL | 0.4647 mL | 1.1618 mL | |
| 60 mM | 0.0387 mL | 0.1936 mL | 0.3873 mL | 0.9682 mL | |
| 80 mM | 0.0290 mL | 0.1452 mL | 0.2904 mL | 0.7261 mL | |
| 100 mM | 0.0232 mL | 0.1162 mL | 0.2324 mL | 0.5809 mL |